EPISODE · Nov 12, 2025 · 12 MIN
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
from BiotechTV - News · host BiotechTV
CEO Michael Henderson walks us through what will be a busy year for the company.
What this episode covers
CEO Michael Henderson walks us through what will be a busy year for the company.
NOW PLAYING
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m